Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nandini Raghavan

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
AJR. American Journal of Roentgenology|March 13, 2019
Automated Tracking of Follow-Up Imaging RecommendationsThusitha Mabotuwana, Christopher S Hall, Vadiraj Hombal, et al.
Genes, Chromosomes & Cancer|July 30, 2008
Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arraysMarianne Tuefferd, An De Bondt, Ilse Van Den Wyngaert, et al.
Proteomics. Clinical Applications|February 14, 2015
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSFDaniel S Spellman, Kristin R Wildsmith, Lee A Honigberg, et al.
Journal of Neurology|March 25, 2026
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension studyXavier Montalban, Reinhard Hohlfeld, Carlo Pozzilli, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 5, 2011
Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the ratMark R Fielden, Alex Adai, Robert T Dunn, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL StudySamantha C Burnham, Nandini Raghavan, William Wilson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2021
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseOndrej Libiger, Leslie M Shaw, Mark H Watson, et al.
JAMA Neurology|January 19, 2021
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical TrialReisa Sperling, David Henley, Paul S Aisen, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative DiseasesDiane Stephenson, Enrique Aviles, Lisa J Bain, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 23, 2015
Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort studyYuk Yee Leung, Jon B Toledo, Alexey Nefedov, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
AJR. American Journal of Roentgenology|March 13, 2019
Automated Tracking of Follow-Up Imaging RecommendationsThusitha Mabotuwana, Christopher S Hall, Vadiraj Hombal, et al.
Genes, Chromosomes & Cancer|July 30, 2008
Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arraysMarianne Tuefferd, An De Bondt, Ilse Van Den Wyngaert, et al.
Proteomics. Clinical Applications|February 14, 2015
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSFDaniel S Spellman, Kristin R Wildsmith, Lee A Honigberg, et al.
Journal of Neurology|March 25, 2026
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension studyXavier Montalban, Reinhard Hohlfeld, Carlo Pozzilli, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|August 5, 2011
Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the ratMark R Fielden, Alex Adai, Robert T Dunn, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL StudySamantha C Burnham, Nandini Raghavan, William Wilson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2021
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseOndrej Libiger, Leslie M Shaw, Mark H Watson, et al.
JAMA Neurology|January 19, 2021
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical TrialReisa Sperling, David Henley, Paul S Aisen, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative DiseasesDiane Stephenson, Enrique Aviles, Lisa J Bain, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 23, 2015
Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort studyYuk Yee Leung, Jon B Toledo, Alexey Nefedov, et al.
Pageof 4